Want to advertise a product or service on Green Prophet? Email [email protected]

Cannabis and autism in children, a new study supporting the trends

Invest in CBD and medical cannabis guide

Scientists in Haifa, Israel have developed a new path for understanding how cannabis-extracted CBD helps children with autism. They have found that preparations of CBD-rich cannabis products or extracts reduce anxiety and other autistic symptoms in children, according to data published in the journal Cannabis and Cannabinoid Research. Ayelet David and Eynat Gal led the study out of Haifa University.

Israeli scientists assessed the efficacy of CBD-dominant cannabis extracts in a cohort of 65 children (ages 5-12 years) with autism. Study participants consumed customized doses of cannabis extracts for six months.

Related: A look at cannabis and autism

“We observed significant differences in the autistic children’s overall anxiety and in some anxiety subtypes. Significant improvements were observed in RRBI [restricted and repetitive behaviors and interests], including the total score, and specifically in compulsive, ritualistic, and sameness behaviors,” reported the researchers who concluded that “Our study suggests positive implications for CBD-rich cannabis treatment in alleviating anxiety and RRBI symptoms in autistic children.

“We strongly recommend further double-blind, placebo-controlled studies using standardized assessments to validate these findings.”

The findings are consistent with other studies which find that cannabinoid (or CBD) treatment provides symptom improvements in children with autism. We have consulted with Dr. Alan Shackleford, a leading physician in medical cannabis in the United States and Israel, who has also said to us in personal communication that he believes some amount of THC is needed to see an effect.

Observational studies have also shown that the use of cannabis can provide benefits to adults with autism. In 2023, a randomized trial from Israel compared CBD-enriched extract (20:1 CBD:THC) and purified cannabinoids in the same ratio to placebo in a three-arm crossover design in 150 patients with autism aged 5 to 21 years.

The authors reported tolerability with improvements in disruptive behaviours and core autism symptoms.

 

Facebook Comments
Karin Kloosterman
Author: Karin Kloosterman

Karin Kloosterman is an award-winning journalist, innovation strategist, and founder of Green Prophet, one of the Middle East’s pioneering sustainability platforms. She has ranked in the Top 10 of Verizon innovation competitions, participated in NASA-linked challenges, and spoken worldwide on climate, food security, and future resilience. With an IoT technology patent, features in Canada’s National Post, and leadership inside teams building next-generation agricultural and planetary systems — including Mars-farming concepts — Karin operates at the intersection of storytelling, science, and systems change. She doesn’t report on the future – she helps design it. Reach out directly to [email protected]

Share

PinIt
submit to reddit

About Karin Kloosterman

Karin Kloosterman is an award-winning journalist, innovation strategist, and founder of Green Prophet, one of the Middle East’s pioneering sustainability platforms. She has ranked in the Top 10 of Verizon innovation competitions, participated in NASA-linked challenges, and spoken worldwide on climate, food security, and future resilience. With an IoT technology patent, features in Canada’s National Post, and leadership inside teams building next-generation agricultural and planetary systems — including Mars-farming concepts — Karin operates at the intersection of storytelling, science, and systems change. She doesn’t report on the future – she helps design it. Reach out directly to [email protected]

Get featured on Green Prophet [email protected]